Parkinson’s disease: Cerevance outlines Phase II/III trial planned for Q1 2023
Cerevance CMO Jordan Dubow shares exclusive details on the first of two planned registrational trials in Parkinson’s disease.
By
Follow @WillNewton19
William Newton is a senior reporter for Clinical Trials Arena and Pharmaceutical Technology, focusing on clinical trial design, rare diseases, and the central nervous system. Now based in New York City, he previously covered diabetes drug development at Close Concerns’ industry-facing publication in San Francisco. William holds a BA in Economics from Williams College.
Cerevance CMO Jordan Dubow shares exclusive details on the first of two planned registrational trials in Parkinson’s disease.
By William NewtonAfter Biogen all but waved the white flag on its once-promising Aduhelm, Clinical Trials Arena explores how Alzheimer’s disease…
By William NewtonSome ultra-rare diseases have fewer than 30 known patients globally. Is there an ethical and economical way to test…
By William NewtonCNM-Au8 clinical advisor Matthew Kiernan previews Clene’s planned Phase III ALS trial design, including biomarkers and target population.
By William NewtonNeuroSense CEO Alon Ben-Noon reveals the target patient population and outcome measures of a planned Phase IIb ALS trial…
By William NewtonThe 6-minute walk test has long been the consensus primary measure for Pompe disease drug studies, but some experts…
By William NewtonBrainStorm Cell Therapeutics is generating stem cells to test its ALS drug in a genetic subpopulation after missing the…
By William NewtonWe highlight our coverage on amyotrophic lateral sclerosis, Huntington’s disease, Rett syndrome, and achondroplasia for Rare Disease Day.
By William NewtonWe also review Regenxbio in mucopolysaccharidosis type I and four Phase I trial updates.
By William Newton and Urtė Fultinavičiūtė